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Cobalamin measurement is routinely performed for the screening of vitamin B12
deficiency. Unfortunately, there is no consensus on standardization and no
consensus on thresholds used for deficiency. Hence, there is variability between
the results of different Vitamin B12 methods leading to potentially different
clinical interpretation of the results. In this study, we decided to compare
automated assays for cobalamin determination within two different populations,
normal and at risk of deficiency.
Material and Methods
Cobalamin was measured with two different automated immunoassay analyzers:
Abbott Architect i1000sr and Roche Modular e602. We compared the two
immunoassays in two separate cohorts. The first one consisted of 80 healthy
people and the second one consisted of 108 metformin-treated type 2 diabetic
patients. Serum cobalamin concentrations were classified as deficient (<200
ng/L), borderline (200-300 ng/L) and sufficient (>300 ng/L).
Statistical analysis:
MedCalc software, version 12.7.7.0 (Oostende, Belgium) was used to perform
the Passing-Bablok regressions and Bland-Altman plot.
Conclusions
There was a systematic and a proportional bias between both
assays, found similarly in the two cohorts. Results obtained
with Abbott were lower than those obtained with Roche and
could potentially lead to earlier supplementation. Due to
variability of cobalamin results between different
manufacturers, cut-off values for deficiency should be verified
for each laboratory to avoid misclassification.
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